March 30 (Reuters) - AstraZeneca PLC:
* ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901
* ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901
* CMG901 IS CURRENTLY BEING EVALUATED IN A PHASE I TRIAL FOR TREATMENT OF CLAUDIN 18.2-POSITIVE SOLID TUMOURS, INCLUDING GASTRIC CANCER
* PRELIMINARY RESULTS FROM TRIAL SHOWN ENCOURAGING PROFILE FOR CMG901, WITH EARLY SIGNS OF ANTI-TUMOUR ACTIVITY ACROSS DOSE LEVELS TESTED Source text for Eikon: Further company coverage: